Differences in cutaneous melanoma survival between the 7th and 8th edition of the American Joint Committee on Cancer (AJCC). A multicentric population-based study.

[1]  W. V. van Houdt,et al.  External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment? , 2020, Melanoma research.

[2]  C. Garbe,et al.  Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. , 2019, European journal of cancer.

[3]  J. Malvehy,et al.  Evaluating polygenic risk score prediction model for melanoma prognosis , 2019, Annals of Oncology.

[4]  D. Schadendorf,et al.  Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma. , 2019, European journal of cancer.

[5]  P. Ascierto,et al.  Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. , 2019, European journal of cancer.

[6]  J. Malvehy,et al.  Survival analysis and sentinel lymph node status in thin cutaneous melanoma: A multicenter observational study , 2019, Cancer medicine.

[7]  B. Gastman,et al.  Gene expression profiling in melanoma: past results and future potential. , 2019, Future oncology.

[8]  J. Malvehy,et al.  Early outcome of a 31‐gene expression profile test in 86 AJCC stage IB‐II melanoma patients. A prospective multicentre cohort study , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  Rajiv Kumar,et al.  TERT promoter mutations in melanoma survival , 2019, Oncotarget.

[10]  R. Ionescu-Ittu,et al.  Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study. , 2019, Future oncology.

[11]  Rajiv Kumar,et al.  TERT promoter mutation subtypes and survival in stage I and II melanoma patients , 2018, International journal of cancer.

[12]  V. Prieto,et al.  Update on eighth edition American Joint Committee on Cancer classification for cutaneous melanoma and overview of potential pitfalls in histological examination of staging parameters , 2018, Journal of Clinical Pathology.

[13]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[14]  J. Gershenwald,et al.  The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care , 2018, Expert review of anticancer therapy.

[15]  R. Scolyer,et al.  Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond , 2018, Annals of Surgical Oncology.

[16]  O. Abdel-Rahman.  Evaluation of the eighth American Joint Committee on Cancer staging system for malignant melanoma of the skin. , 2018, Future oncology.

[17]  A. Hauschild,et al.  Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. , 2017, European journal of cancer.

[18]  Jeffrey E Gershenwald,et al.  Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[19]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[20]  P. Ascierto,et al.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.

[21]  A. Hauschild,et al.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.

[22]  K. Flaherty,et al.  Targeted agents and immunotherapies: optimizing outcomes in melanoma , 2017, Nature Reviews Clinical Oncology.

[23]  D. Rigel,et al.  Analysis of Trends in US Melanoma Incidence and Mortality , 2017, JAMA dermatology.

[24]  K. Hemminki,et al.  TERT promoter mutations in melanoma survival , 2019, Oncotarget.

[25]  F. Wright,et al.  Sentinel Lymph Node Biopsy in Thin Cutaneous Melanoma: A Systematic Review and Meta-Analysis , 2016, Annals of surgical oncology.

[26]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[27]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[28]  J. Utikal,et al.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.

[29]  V. Sondak,et al.  Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  K. Shannon,et al.  Sentinel Lymph Node Biopsy in Patients With Thin Primary Cutaneous Melanoma , 2012, Annals of surgery.

[31]  C. Balch,et al.  Implications of the 2009 American Joint Committee on Cancer Melanoma Staging and Classification on dermatologists and their patients. , 2010, Seminars in cutaneous medicine and surgery.

[32]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  S. Pocock,et al.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration , 2007, PLoS medicine.

[34]  A. Eggermont,et al.  The development of optimal pathological assessment of sentinel lymph nodes for melanoma , 2003, The Journal of pathology.

[35]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[36]  G. Boland,et al.  Principles of Melanoma Staging. , 2016, Cancer treatment and research.

[37]  B K Armstrong,et al.  Melanoma of the skin. , 1984, British medical bulletin.